Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer

Romano Danesi, Filippo De Braud, Stefano Fogli, Tommaso Martino De Pas, Antonello Di Paolo, Giuseppe Curigliano, Mario Del Tacca

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

In mammalian cells, the process of malignant transformation is characterized by the loss or down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-oncogenes, whose products promote dysregulated proliferation of cells and extend their life span. Deregulation in intracellular transduction pathways generates mitogenic signals that promote abnormal cell growth and the acquisition of an undifferentiated phenotype. Genetic abnormalities in cancer have been widely studied to identify those factors predictive of tumor progression, survival, and response to chemotherapeutic agents. Pharmacogenetics has been founded as a science to examine the genetic basis of interindividual variation in drug metabolism, drug targets, and transporters, which result in differences in the efficacy and safety of many therapeutic agents. The traditional pharmacogenetic approach relies on studying sequence variations in candidate genes suspected of affecting drug response. However, these studies have yielded contradictory results because of the small number of molecular determinants of drug response examined, and in several cases this approach was revealed to be reductionistic. This limitation is now being overcome by the use of novel techniques, i.e., highdensity DNA and protein arrays, which allow genome and proteome-wide tumor profiling. Pharmacogenomics represents the natural evolution of pharmacogenetics since it addresses, on a genome-wide basis, the effect of the sum of genetic variants on drug responses of individuals. Development of pharmacogenomics as a new field has accelerated the progress in drug discovery by the identification of novel therapeutic targets by expression profiling at the genomic or proteomic levels. In addition to this, pharmacogenetics and pharmacogenomics provide an important opportunity to select patients who may benefit from the administration of specific agents that best match the genetic profile of the disease, thus allowing maximum activity.

Original languageEnglish
Pages (from-to)57-103
Number of pages47
JournalPharmacological Reviews
Volume55
Issue number1
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Pharmacogenetics
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Genome
Neoplasms
Protein Array Analysis
Inborn Genetic Diseases
Proto-Oncogenes
Oncogene Proteins
Drug Discovery
Proteome
Oligonucleotide Array Sequence Analysis
Tumor Suppressor Genes
Proteomics
Down-Regulation
Cell Proliferation
Phenotype
Safety
Mutation
Survival

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. / Danesi, Romano; De Braud, Filippo; Fogli, Stefano; De Pas, Tommaso Martino; Di Paolo, Antonello; Curigliano, Giuseppe; Del Tacca, Mario.

In: Pharmacological Reviews, Vol. 55, No. 1, 03.2003, p. 57-103.

Research output: Contribution to journalArticle

Danesi, Romano ; De Braud, Filippo ; Fogli, Stefano ; De Pas, Tommaso Martino ; Di Paolo, Antonello ; Curigliano, Giuseppe ; Del Tacca, Mario. / Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. In: Pharmacological Reviews. 2003 ; Vol. 55, No. 1. pp. 57-103.
@article{06e2f97030ca4ea797f8a827d0ca52ae,
title = "Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer",
abstract = "In mammalian cells, the process of malignant transformation is characterized by the loss or down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-oncogenes, whose products promote dysregulated proliferation of cells and extend their life span. Deregulation in intracellular transduction pathways generates mitogenic signals that promote abnormal cell growth and the acquisition of an undifferentiated phenotype. Genetic abnormalities in cancer have been widely studied to identify those factors predictive of tumor progression, survival, and response to chemotherapeutic agents. Pharmacogenetics has been founded as a science to examine the genetic basis of interindividual variation in drug metabolism, drug targets, and transporters, which result in differences in the efficacy and safety of many therapeutic agents. The traditional pharmacogenetic approach relies on studying sequence variations in candidate genes suspected of affecting drug response. However, these studies have yielded contradictory results because of the small number of molecular determinants of drug response examined, and in several cases this approach was revealed to be reductionistic. This limitation is now being overcome by the use of novel techniques, i.e., highdensity DNA and protein arrays, which allow genome and proteome-wide tumor profiling. Pharmacogenomics represents the natural evolution of pharmacogenetics since it addresses, on a genome-wide basis, the effect of the sum of genetic variants on drug responses of individuals. Development of pharmacogenomics as a new field has accelerated the progress in drug discovery by the identification of novel therapeutic targets by expression profiling at the genomic or proteomic levels. In addition to this, pharmacogenetics and pharmacogenomics provide an important opportunity to select patients who may benefit from the administration of specific agents that best match the genetic profile of the disease, thus allowing maximum activity.",
author = "Romano Danesi and {De Braud}, Filippo and Stefano Fogli and {De Pas}, {Tommaso Martino} and {Di Paolo}, Antonello and Giuseppe Curigliano and {Del Tacca}, Mario",
year = "2003",
month = "3",
doi = "10.1124/pr.55.1.4",
language = "English",
volume = "55",
pages = "57--103",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer

AU - Danesi, Romano

AU - De Braud, Filippo

AU - Fogli, Stefano

AU - De Pas, Tommaso Martino

AU - Di Paolo, Antonello

AU - Curigliano, Giuseppe

AU - Del Tacca, Mario

PY - 2003/3

Y1 - 2003/3

N2 - In mammalian cells, the process of malignant transformation is characterized by the loss or down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-oncogenes, whose products promote dysregulated proliferation of cells and extend their life span. Deregulation in intracellular transduction pathways generates mitogenic signals that promote abnormal cell growth and the acquisition of an undifferentiated phenotype. Genetic abnormalities in cancer have been widely studied to identify those factors predictive of tumor progression, survival, and response to chemotherapeutic agents. Pharmacogenetics has been founded as a science to examine the genetic basis of interindividual variation in drug metabolism, drug targets, and transporters, which result in differences in the efficacy and safety of many therapeutic agents. The traditional pharmacogenetic approach relies on studying sequence variations in candidate genes suspected of affecting drug response. However, these studies have yielded contradictory results because of the small number of molecular determinants of drug response examined, and in several cases this approach was revealed to be reductionistic. This limitation is now being overcome by the use of novel techniques, i.e., highdensity DNA and protein arrays, which allow genome and proteome-wide tumor profiling. Pharmacogenomics represents the natural evolution of pharmacogenetics since it addresses, on a genome-wide basis, the effect of the sum of genetic variants on drug responses of individuals. Development of pharmacogenomics as a new field has accelerated the progress in drug discovery by the identification of novel therapeutic targets by expression profiling at the genomic or proteomic levels. In addition to this, pharmacogenetics and pharmacogenomics provide an important opportunity to select patients who may benefit from the administration of specific agents that best match the genetic profile of the disease, thus allowing maximum activity.

AB - In mammalian cells, the process of malignant transformation is characterized by the loss or down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-oncogenes, whose products promote dysregulated proliferation of cells and extend their life span. Deregulation in intracellular transduction pathways generates mitogenic signals that promote abnormal cell growth and the acquisition of an undifferentiated phenotype. Genetic abnormalities in cancer have been widely studied to identify those factors predictive of tumor progression, survival, and response to chemotherapeutic agents. Pharmacogenetics has been founded as a science to examine the genetic basis of interindividual variation in drug metabolism, drug targets, and transporters, which result in differences in the efficacy and safety of many therapeutic agents. The traditional pharmacogenetic approach relies on studying sequence variations in candidate genes suspected of affecting drug response. However, these studies have yielded contradictory results because of the small number of molecular determinants of drug response examined, and in several cases this approach was revealed to be reductionistic. This limitation is now being overcome by the use of novel techniques, i.e., highdensity DNA and protein arrays, which allow genome and proteome-wide tumor profiling. Pharmacogenomics represents the natural evolution of pharmacogenetics since it addresses, on a genome-wide basis, the effect of the sum of genetic variants on drug responses of individuals. Development of pharmacogenomics as a new field has accelerated the progress in drug discovery by the identification of novel therapeutic targets by expression profiling at the genomic or proteomic levels. In addition to this, pharmacogenetics and pharmacogenomics provide an important opportunity to select patients who may benefit from the administration of specific agents that best match the genetic profile of the disease, thus allowing maximum activity.

UR - http://www.scopus.com/inward/record.url?scp=0037371443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037371443&partnerID=8YFLogxK

U2 - 10.1124/pr.55.1.4

DO - 10.1124/pr.55.1.4

M3 - Article

C2 - 12615954

AN - SCOPUS:0037371443

VL - 55

SP - 57

EP - 103

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 1

ER -